Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis
| Autor: | Kang Shen Yao, Muthu Selvakumaran, Peter J. O'Dwyer, Michael Feldman |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Vascular Endothelial Growth Factor A
Pathology medicine.medical_specialty Programmed cell death Bevacizumab Colorectal cancer Angiogenesis Inhibitors Antineoplastic Agents Apoptosis Mice SCID Biology Antibodies Monoclonal Humanized Biochemistry Article Mice medicine Animals Humans Pimonidazole Pharmacology Antibodies Monoclonal Cancer HCT116 Cells medicine.disease Cell Hypoxia digestive system diseases Angiogenesis inhibitor Vascular endothelial growth factor A Colonic Neoplasms Cancer research Female HT29 Cells medicine.drug |
| Zdroj: | Biochemical Pharmacology. 75:627-638 |
| ISSN: | 0006-2952 |
| DOI: | 10.1016/j.bcp.2007.09.029 |
| Popis: | Angiogenesis inhibition has been shown to enhance the therapeutic efficacy of cytotoxic chemotherapy in colorectal cancer. The basis of the contribution of this modality has not been defined fully. To determine the potential role of hypoxia-induced apoptosis, we studied a series of colon cancer cell lines with varying susceptibility to hypoxia. We exposed HT29 and HCT116 colon adenocarcinoma cell lines to sublethal periods of hypoxia three times weekly for 40 exposures, and derived cell lines both more resistant (from HT29) and more sensitive (from HCT116) to hypoxia-induced apoptosis. Both hypoxia-derived cell lines demonstrated more rapid growth than the parental lines when implanted subcutaneously in immunodeficient mice. Treatment of tumor-bearing mice with bevacizumab resulted in depletion of tumor microvasculature, upregulation of Hypoxia-inducible factor-1 alpha (HIF-1alpha), and increased pimonidazole staining, consistent with an anti-angiogenic effect and induction of hypoxia in tumors derived from all cell lines. The proportion of apoptotic cells was increased in all the treated tumors, and was most pronounced in the bevacizumab-treated HCT116-derived cells. The bevacizumab-treated tumors showed growth delay in HT29 and its derivative, and the parental HCT116. In the hypoxia-sensitive HCT116-derived tumors, marked tumor shrinkage and prolonged growth control occurred. Therefore, bevacizumab treatment is an effective inducer of a hypoxic environment, but the resulting cell kill and tumor shrinkage is determined by the susceptibility of the tumor to apoptosis. The induction of apoptosis by hypoxia may contribute to the benefits of such treatment in the clinical setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect